NCT06080646Completed
Reward Processing and Depressive Subtypes: Identifying Neural Biotypes
Reward Processing and Depressive Subtypes: Identifying Neural Biotypes Related to Suicide Risk, Resilience, and Treatment Response
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception, including individual variation in symptoms, severity, and treatment response. This heterogeneity complicates understanding of depression and thwarts progress toward disease classification and treatment planning. Discovery of depression-specific biomarkers that account for neurobiological variation that presumably underlies distinct clinical manifestations is critical to this larger effort.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 158 (actual)
- First submitted
- 28 Sept 2023
- Start date
- 1 Jun 2021
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- San Francisco Veterans Affairs Medical Center
- Diseases
- Depression
- NCT number
- NCT06080646
What you commit to
- Study type: Observational
- Participants enrolled: 158
- From 1 Jun 2021 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major medical conditions (e.g., seizure disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology)
Other illness
- Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive symptoms)
Other
- Loss of consciousness (LOC) greater than 30 minutes or any LOC with neurologic symptoms
- Substance dependence, within the past year, or failed urine toxicology on the day of neuroimaging sessions
- Known claustrophobia
- Current Pregnancy
- IQ estimate \< 70
Who the study is looking for
- 18-70 years with a diagnosis of major depressive disorder (MDD) for MDD group, or without for unaffected comparison (UC) group
- Negative metal screen for MRI safety
- Normal (or corrected to normal) vision
Criteria the registry did not label
- Our studies require some in-person visits to our research lab, located at 42nd Ave and Clement St in San Francisco.
- Because this study includes an MRI, part of the screening process will be to ensure you don't have any metal in your body, you do not have head or neck tattoos, and you are comfortable inside the MRI scanner.
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| San Francisco Healthcare System Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.